# DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $6,457,269

## Abstract

The Division of Cancer Treatment and Diagnosis, NCI is requesting support for the development and production of canine-specific agonists and/or antagonist antibodies to support immunotherapy studies in companion canines

## Key facts

- **NIH application ID:** 10502671
- **Project number:** 75N91019D00024-0-759102100016-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** VICKIE COLEMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $6,457,269
- **Award type:** —
- **Project period:** 2021-09-16 → 2025-09-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10502671

## Citation

> US National Institutes of Health, RePORTER application 10502671, DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS (75N91019D00024-0-759102100016-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10502671. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*